Literature DB >> 8617704

The making of a user friendly MAOI diet.

D M Gardner1, K I Shulman, S E Walker, S A Tailor.   

Abstract

BACKGROUND: Many monoamine oxidase inhibitor (MAOI) diets are considered to be excessively restrictive and founded on poor scientific evidence. We present a safe and practical MAOI diet based on the related clinical and analytic data.
METHOD: We used a critical review of the literature and our own tyramine assay results to categorize foods to be restricted absolutely, taken in moderation only, or unrestricted.
RESULTS: We recommend that users avoid aged cheese; aged or cured meats (e.g., air-dried sausage); any potentially spoiled meat, poultry, or fish; broad (fava) bean pods; Marmite concentrated yeast extract; sauerkraut; soy sauce and soy bean condiments; and tap beer. Wine and domestic bottled or canned beer are considered safe when consumed in moderation. Other foods not mentioned are considered unrestricted.
CONCLUSION: The concerns about perpetuating an overly restrictive MAOI diet include the avoidance by prescribers of a potentially useful treatment option, excessive limitations on lifestyle for patients, and increased risk to patients secondary to noncompliance with the diet. We propose an MAOI diet that has a solid scientific and clinical basis and that is, above all, practical.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617704

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

Review 1.  Pharmacological treatment of depression in children and adolescents.

Authors:  R L Findling; M D Reed; J L Blumer
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

Review 2.  The association between conventional antidepressants and the metabolic syndrome: a review of the evidence and clinical implications.

Authors:  Roger S McIntyre; Ka Young Park; Candy W Y Law; Farah Sultan; Amanda Adams; Maria Teresa Lourenco; Aaron K S Lo; Joanna K Soczynska; Hanna Woldeyohannes; Mohammad Alsuwaidan; Jinju Yoon; Sidney H Kennedy
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

3.  The role of monoamine oxidase inhibitors in current psychiatric practice.

Authors:  Jess G Fiedorowicz; Karen L Swartz
Journal:  J Psychiatr Pract       Date:  2004-07       Impact factor: 1.325

4.  Improving the oral bioavailability of beneficial polyphenols through designed synergies.

Authors:  Arjan Scheepens; Kee Tan; James W Paxton
Journal:  Genes Nutr       Date:  2009-10-20       Impact factor: 5.523

5.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

6.  Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor.

Authors:  José V Pardo
Journal:  Gen Hosp Psychiatry       Date:  2011-10-02       Impact factor: 3.238

7.  Food-drug interactions.

Authors:  Rabia Bushra; Nousheen Aslam; Arshad Yar Khan
Journal:  Oman Med J       Date:  2011-03

8.  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.

Authors:  Daniel Z Lieberman; Suena H Massey
Journal:  Core Evid       Date:  2010-06-15

Review 9.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

10.  Reducing the Burden of Difficult-to-Treat Major Depressive Disorder: Revisiting Monoamine Oxidase Inhibitor Therapy.

Authors:  Larry Culpepper
Journal:  Prim Care Companion CNS Disord       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.